Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 194

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 194
---
 of this value, approximately 3,837,000    
 shares of FutureTech common stock, is currently estimated to be allocated to the unitholders of Aegeria who will become stockholders of      
 Longevity via Longevity’s acquisition of the Targets immediately prior to the Business Combination. The fair value of Aegeria is             
 estimated to be the fair value of the 3,837,000 shares of FutureTech common stock the Aegeria unitholders will be receiving in the Business  
 Combination, which is currently estimated to be $11.80 per share based on the January 23, 2025 closing price of FutureTech Class A common    
 stock. If the FutureTech stock price were to increase to $13.00 or $14.00 per share, then the estimated purchase price of Aegeria would      
 increase by $4.6 million and $8.4 million, respectively. If the FutureTech stock price were to decrease to $11.00 or $10.00 per share,       
 the estimated purchase price of Aegeria would decrease by $3.1 million and $6.9 million, respectively. Each change in the estimated purchase 
 price of Aegeria would have a corresponding impact to the value of the acquired in-process research and development.                         |

| (iii) | IPR&D represents the research and development project of Aegeria which was in-process, but not yet                                     
 completed, and which Longevity plans to advance. This includes the development of Aegeria’s clinical stage biomatrix technology        
 for the treatment of soft tissue defects. Current accounting standards require that the fair value of IPR&D projects acquired in an    
 asset acquisition with no alternative future use be allocated a portion of the consideration transferred and charged to expense at the 
 acquisition date. The acquired set of assets and liabilities did not have outputs or employees. The actual purchase price allocated to 
 IPR&D will fluctuate until the final transaction costs and the actual amount of cash used for Aegeria’s operations are known.          
 The final valuation of the IPR&D consideration could differ significantly from the current                                             
 estimate.                                                                                                                              |

| 91 |

Note 3 — Target Acquisitions
Pro Forma Adjustments

Given Cerevast’s
history of net losses and valuation allowance, management assumed a statutory tax rate of zero percent. Therefore, the pro forma adjustments
to the statement of operations resulted in no additional income tax adjustment to the pro forma financials.

The pro forma
adjust